Revitalizing Healthcare.

Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families.

WHO WE ARE

About Us

Roivant provides solutions to the biopharmaceutical industry and academic institutions through partnerships that advance the development of promising investigational medicines currently stuck in an industry-wide R&D ‘traffic jam.’ Our long-range mission is to reduce the time and cost of developing these new therapies for patients and to share those savings with the broader healthcare system.

Roivant is the parent company of a growing family of companies focused on distinct therapeutic areas. At present the Roivant Sciences Group includes two majority-owned public subsidiary companies (Axovant and Myovant) and three wholly-owned private subsidiary companies (Enzyvant, Dermavant, and Urovant). Our pipeline currently includes 14 investigational drugs across many areas of significant medical need.

Roivant continues to launch new subsidiary companies focused on making significant advances in healthcare and supports its existing companies as they become leaders in their respective fields.

 

OUR FAMILY

Axovant

Finding new solutions
for dementia.

OUR FAMILY

Myovant

Dedicated to women’s health and prostate cancer.

OUR FAMILY

Enzyvant

Developing transformative therapies for patients with rare diseases.

OUR FAMILY

Dermavant

Leading innovation in medical dermatology.

OUR FAMILY

Urovant

Improving quality of life
through innovations in urology.

OUR WORK

Pipeline

We have a diverse pipeline of 14 investigational drugs in 6 therapeutic areas being tested in 39 clinical trials across our family of companies.

THERAPEUTIC AREA
COMPOUND
INDICATION
PHASE
therapeutic area Compound Indication PRECLIN Phase 1 Phase 2 Phase 3
NEUROLOGY INTEPIRDINE

Mild-to-Moderate Alzheimer's Disease

3

Dementia with Lewy Bodies (DLB)

2

Gait and Balance Impairments in Dementia

2

NELOTANSERIN

Visual Hallucinations in Lewy Body Dementia

2

REM Behavior Disorder (RBD) in DLB

2

RVT-103 and RVT-104

Alzheimer's Disease

1

ONCOLOGY RELUGOLIX

Prostate Cancer

3

ENDOCRINOLOGY RELUGOLIX

Uterine Fibroids

3

Endometriosis

3

MVT-602

Female Infertility

Preclin

RARE DISEASES RVT-801

Farber Disease

Preclin

RVT-802

Complete DiGeorge Syndrome

3

DERMATOLOGY RVT-501

Mild-to-Moderate Atopic Dermatitis

2

RVT-502

Moderate-to-Severe Dermatologic Indications

Preclin

RVT-201

Inflammatory Skin Diseases

1

UROLOGY VIBEGRON

Overactive Bladder

3

OTHER RVT-701

Autism

2

RVT-702

Undisclosed

Preclin

OUR PEOPLE

Leadership

Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.

The management teams of our subsidiary companies feature some of the most accomplished executives in the biopharmaceutical industry.

Our directors have deep experience in pharmaceutical business development, academic research, public policy, and life sciences investing.

Our Public Stakeholder Advisory Group (PSAG) provides continuing advice on how Roivant can play a role in improving the healthcare system.

WHO WE WORK WITH

Partners

We work with partners who share our patient-centric commitment to developing new medicines, helping them realize value from potential therapies beyond their core areas of focus. We seek investigational drugs with the potential to have a transformative impact on the lives of patients.

STAY INFORMED

News

GET IN TOUCH

Contact Us

Basel, Switzerland
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
New York, NY
Roivant Sciences, Inc.
320 West 37th Street
5th Floor
New York, NY 10018
United States
Durham, NC
Roivant Sciences, Inc.
324 Blackwell St
Bay 12, Suite #1220
Durham, NC 27701
United States
San Francisco, CA
Myovant Sciences, Inc.
2000 Sierra Point Parkway
5th Floor
Brisbane, CA 94005
United States
Cambridge, MA
Enzyvant Sciences, Inc.
90 Broadway
Suite 204
Cambridge, MA 02142
United States